Ross手术与无支架生物瓣在急性主动脉瓣感染性心内膜炎中的作用
本研究比较了1997至2023年间132例18至60岁主动脉瓣感染性心内膜炎患者接受Ross手术、机械瓣或生物瓣主动脉瓣置换的中期结果。随访显示Ross手术长期生存良好且瓣膜相关并发症最低,无支架生物瓣根部置换可作为50岁以上患者的替代选择,而补片隔绝脓肿后瓣膜置换结果较差。
要点
- Ross手术治疗主动脉瓣感染性心内膜炎长期生存良好且瓣膜相关并发症最低。
- 50岁以上患者可考虑无支架生物瓣根部置换作为替代选择。
- 补片隔绝脓肿后行瓣膜置换与较差结果相关。
核心结论
- Ross手术和无支架生物瓣长期生存良好,Ross手术瓣膜相关并发症最低。
- Ross手术与无支架生物瓣根部再手术率相似且不可忽视。
- 补片隔绝脓肿后瓣膜置换与较差结果相关。
- 50岁以上患者无支架生物瓣根部置换可能为替代选择。
研究设计与样本
- 回顾性比较研究,纳入1997至2023年176例18至60岁因主动脉瓣感染性心内膜炎手术患者。
- 排除44例主动脉瓣修复后,分析132例(男性82%,平均年龄46±11岁)。
- 手术方式:Ross手术32例,机械瓣主动脉瓣置换28例,生物瓣主动脉瓣置换72例。
- 中位随访6.4年(IQR 2.1-12.9),平均随访7.9±6.6年(共1041患者年)。
主要发现
- 15例(11%;Ross 1例,生物瓣11例,机械瓣3例;P=.028)复发感染性心内膜炎。
- 15年生存率总体78%(Ross 92%;生物瓣72%;机械瓣70%;P=.176)。
- 15年时自体瓣膜感染性心内膜炎后生存79%,人工瓣膜后73%(P=.622)。
- 15年时生物瓣主动脉瓣置换后生存66%,根部置换后93%(P=.05)。
临床怎么用
- 年轻主动脉瓣感染性心内膜炎患者可优先考虑Ross手术以降低瓣膜相关并发症。
- 50岁以上患者无支架生物瓣根部置换可作为Ross手术的替代选择。
- 应避免补片隔绝脓肿后行瓣膜置换,因其与较差结果相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Infective endocarditis (IE) is associated with high morbidity and mortality; nearly 40% present with isolated aortic valve (AV) endocarditis. No detailed guidelines on surgical strategies are currently available particularly for younger patients. The aim of this study was to compare mid-term results of conventional valve (aortic valve replacement [AVR]) and root replacement and the Ross procedure in patients <60 years. METHODS: Between 1997 and 2023, 176 patients >18 and <60 years underwent surgery for AV IE. Patients with AV repair (n = 44) were excluded; the remaining 132 (male 82%; mean age 46 ± 11 years) underwent a Ross procedure (n = 32), mechanical AVR (n = 28), biological AVR (n = 72). Median and mean follow-up were 6.4 (IQR 2.1-12.9) years and 7.9 ± 6.6 years (1041 patient-years). RESULTS: Twenty-seven patients (20%; Ross n = 1, biological AVR n = 20, mechanical AVR n = 6; P = .033) required permanent pacemaker implantation, 15 patients had recurrent endocarditis (11%; Ross n = 1, biological AVR n = 11, mechanical AVR n = 3; P = .028). Survival was 78% at 15 years (Ross 92%; biological AVR 72%; mechanical AVR 70%; P = .176). At 15 years, it was 79% after native valve and 73% after prosthetic valve IE (P = .622), and 66% after biological AVR and 93% after root replacement (P = .05). At 15 years, freedom from AV reoperation was 72% (Ross 73%; biological stented AVR 58%; biological stentless root replacement 76%; mechanical AVR 82%; P = .453). CONCLUSIONS: Long-term survival was good after the Ross procedure and stentless biological valves but was best after the Ross procedure with the lowest valve-related complications. Reoperation was non-negligible but similar between the Ross procedure and the stentless biological root. Abscess exclusion with a patch and subsequent valve replacement was associated with inferior results. The Ross procedure offers the best potential for true long-term durability. In patients >50 years, stentless biological root replacement may be an alternative.
引用
- Abeln KB, Becker SL, Müller SE, et al. Role of the Ross Procedure and Stentless Biological Prostheses in Acute Aortic Valve Endocarditis. Eur J Cardiothorac Surg. 2026. PMID: 41408077. doi:10.1093/ejcts/ezaf460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。